Handrean Soran


University Department of Medicine, Central Manchester University, Hospitals NHS Foundation Trust,
Ground Floor, Old St Mary’s Building, Manchester, M13 9WL, UK
2010 MD University of Manchester
2009 FRCP Royal College of physicians-Edinburgh
2006 Certificate Completion Speciality Training in Endocrinology & Diabetes and General Internal Medicine 2006, Royal College of Physicians-UK.
2006 M.Sc Diabetes and Endocrinology University of Liverpool
1999 MRCP Royal college of physicians-Edinburgh
1990 MBChB Al-Mustansyria University, Baghdad, Iraq
Current position:
Consultant Physician & Endocrinologist. Start date: November 2006.
Speciality Endocrinology & Diabetes
General Internal Medicine,
Sub-speciality:Lipidology & cardiovascular Medicine Parathyroid, Calcium & Metabolic Bone Disease
Other positions and duties:
Clinical Lead University Department of Medicine.
Lead Cardiovascular Trials Unit, University Department of Medicine, Central Manchester University Hospital NHS Foundation Trust.
Chief investigator on two academic studies and PI on one.
Supervised 1 PhD and 1 MD students successfully.
I currently supervising 3 PhD students and 1 MD student.
Associate programme director and education lead endocrinology and diabetes North West deanery.
Speciality education lead Endocrinology and Diabetes, Central Manchester University Hospitals.
Previous posts
2003-2006 Specialist registrar in Endocrinology and Diabetes, North West Deanery.
2001-2003 Specialist registrar in Clinical Chemistry and Metabolic Medicine, Mersey Deanery.
2000-2001 Registrar in Endocrinology and Diabetes (LAT), Mersey Deanery.
1998-2001 Senior house officer in medicine and medical specialities University Hosiltal South Manchester and Wirral University Hospital.
Research grants and fund raising
Synageva research grant to support an investigator led study, £20 000 (PI Handrean Soran, 2014-2016)
Greater Manchester CLRN grant to support cardiovascular trials unit’s manpower, £140 000 from 2013-2014 (PI Handrean Soran, April 2013-April 2014)
More than £75 000 from various education activities including courses, lecturing, national and national meetings to support our groups research activities (2008-2013).
Greater Manchester CLRN grant to support Cardiovascular Trials Unit’s manpower April 2012-April 2013, £120 000 (PI Handrean Soran, April 2012- April 2013).
Greater Manchester CLRN to support Cardiovascular Trials Unit’s manpower 2011-2012, £110 000 from (PI Handrean Soran, April 2011-April 2012).
Synageva Investigator led research grant, 2013-2016 £30 000 (PI Handrean Soran).
Manchester WTCRF Research nurse and facility support for a 6 year research project support: Effect of Weight loss, after bariatric surgery, on vascular function, lipoprotein modification, lipoprotein metabolism and HDL function (PI Handrean Soran, September 2012-September 2018).
MSD investigator led project, Effect of Tredaptive on Lipoprotein Modification and HDL Function, £129 000 (PI Handrean Soran 2010-2014).
BHF PhD fellowship value £ 90 000, 2010-2013 (PI Professor Anthony Heagerty, Co-applicant Handrean Soran).
Pfizer investigator led project research; Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin treated patients value £43 000, 2010-2013 (PI Handrean Soran).
1. Rahul Yadav, Yifen Liu, See Kwok, Jonathan Schofield, Michael France, Ruth Eatough, Naveed Younis, Basil Issa, Basil Ammori, Paul N Durrington, Handrean Soran. Effect of Tredaptive therapy on HDL functionality and LDL quality; a double blind randomised crossover trial. Under review ATVB.
2. Jonathan D Schofield, Yifen Liu, Michael W France, Lance Sandle, Handrean Soran. A Review of Paradoxical HDL-C Responses to Fenofibrate; illustrated by a Case Report. Accepted for publication in Journal of Clinical Lipidology.
3. Soran H, Schofield J, Kwok S, Durrington PN. Hyperlipidaemia and its Management. Solicited review article for BMJ 2014.
4. Soran H, Schofield J, Tarza Siahmansur, Durrington PN. Lipoprotein (a): gene genie. Accepted for publication in Current Opinion Lipidology August 2014.
5. Handrean Soran, Jonathan D Schofield and Paul N Durrington. The importance of considering low-density lipoprotein cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy.
6. Rahl Yadav, Michael France, Reza Aghamohammadzadeh, Akheel A. Syed, Rayaz Malik, Adam Greenstein, Paul Durrington, Martin Gibson, Basil Ammori, Maria Jeziorska, Handrean Soran. High Density Lipoprotein Antioxidant Function is Impaired and Adipose Tissue Inflammation is More Pronounced in Obese Patients with Increasing Severity of Obstructive Sleep Apnea. Accepted for publication in JCEM.
7. Zeljko Reiner, Ornella Guardamagna; Davaki Nair; Handrean Soran; Kees Hovingh; Stefano Bertolini; Simon Jones; Marijana Coric; Sebastiano Calandra; John Hamilton; Terence Eagleton; Emilio Ros. Lysosomal acid lipase deficiency – an under-recognized cause of dyslipidaemia and liver dysfunction. Accepted for publication in Atherosclerosis 2014; 235:21-30.
8. Behbehani F1, Ammori BJ, New JP, Summers LK, Soran H, Syed AA. Metabolic outcomes 2 years following gastric bypass surgery in people with type 2 diabetes: an observational cohort study. QJM. 2014 Mar 27. Epub ahead of print.
9. Schofield J, France M, Soran H. Don’t miss familial hypercholesterolaemia in Achilles tendinopathy. BMJ. 2013 Apr 24;346:f2171. doi: 10.1136/bmj.f2171
10.Emmanuel Eroume A Egom, Robert A. Ro; Ludwig Neyses, Handrean Soran, John GF Cleland, Mamas A. Mamas. Statins and Sphingosine-1-phosphate Signalling. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Critical Reviews Clinical Laboratory Science 2013; 50: 79-89.
11.Reza Aghamohammadzadeh, Adam S. Greenstein, Rahul Yadav, Maria Jeziorska, Salam Hama, Fardad Soltani, Phil W. Pemberton, Richard Unwin, Basil Ammori, Handrean Soran, Anthony M. Heagerty. The Effects of Weight-Reducing Surgery on Human Small Artery Function: Evidence for Reduction in Adipocyte Inflammation, and the Restoration of Normal Perivascular Anticontractile Activity Despite Persistent Obesity. JACC 2013; 62: 128-35.
12.Schofield JD, France M, Ammori B, Liu Y, Soran H. High-density lipoprotein cholesterol raising: does it matter? Curr Opin Cardiol. 2013 Jul;28(4):464-74.
13.Egom EE, Mamas MA, Soran H. HDL quality or cholesterol cargo: what really matters – spotlight on sphingosine-1-phosphate-rich HDL. Curr Opin Lipidol 2013; 24: 351-6.
14.Jonathan Schofield, Michael France, Basil J Ammori. HDL-C Raising: Does it Matter? Current Opinion Cardiology 2013; 28: 464-74.
15.McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, Chasan-Taber S. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7(11):e49006.doi:10.1371/journal.pone.0049006.
16.See Kwok, Dexter Canoy, Handrean Soran, David W. Ashton, Gordon D.O. Lowe, D. Wood, Stephen E. Humphries, Paul N Durrington. Smoking, body fat distribution and exogenous hormones in British women. Published on line, Clinical Endocrinology 2012; 77: 828-833.
17.Paisley AJ, Yadav R, Younis N, Rao-Balakrishna P, Soran H. Dapagliflozin : a review on efficacy, clinical effectiveness and safety. Expert Opinion Investigational Drugs 2013; 22: 131-140.
18.Younis NN, Soran H, Pemberton P, Charlton-Menys V, El-Seweidy MM, Durrington PN. Small dense LDL is more susceptible to glycation than more buoyant LDL in type 2 diabetes. Clin Sci (Lond) 2013; 124: 343-9.
19.Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM. UK Consensus Statement on Safe Clinical Prescribing of Bexarotene for Patients with Cutaneous T-cell Lymphoma. Br J Dermatol. 2012 Sep 10. doi: 10.1111/bjd.12042.
20.Younis NN, Soran H, Charlton-Menys V, Sharma R, Hama S, Pemberton P, Elseweidy MM, Durrington PN. High-density lipoprotein impedes glycation of low-density lipoprotein. Diab Vasc Dis Res. 2013; 168:192-200.
21.Soran H, Hama S, Yadav R, Durrington PN. HDL functionality. Curr Opin Lipidol. 2012; 23(4): 353-66.
22.Yadav R, France M, Younis N, Hama S, Ammori BJ, Kwok S, Soran H. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety. Expert Opin Pharmacother. 2012 Jun;13:1345-62.
23.Khavandi K, Brownrigg J, Hankir M, Sood H, Younis N, Worth J, Greenstein A, Soran H, Wierzbicki A, Goldsmith DJ. Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression. Curr Vasc Pharmacol. 2012 Jan 20. [Epub ahead of print].
24.Yadav R, Kwok S, Ammori BJ, Issa B, Soran H. Expert Opin Drug Safity. Safety and tolerability of extended-release niacin with laropiprant. 2012 Jan;11:151-9.
25.Handrean Soran, Valentine Charlton-Menys, Sanjaya Dissanayake, Nahla Younis, Michael France, Paul N Durrington. Apolipoprotein B measurement provides a more consistent goal for statin treatment than low density lipoprotein cholesterol and non high density lipoprotein cholesterol. Ann Clin Biochem. 2011 Nov;48: 566-71
26.Nahla Younis, Handrean Soran, Reena Sharma, Adam Greenstien, Valentine Charlton-Menys, Mahmood M. Elseweidy, Paul N. Durrington. Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin treated type 2 diabetes. Diabetes and Vascular Disease Research 2010; 7: 189-195.
27.Handrean Soran, Valentine Charlton-Menys, Robert Hegele, Jian Wang, Emyr W. Benbow, Ian Roberts, Grahame Wood, Paul Durrington. Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutation
Journal of Clinical Lipidology July 2010; 4: 310-313.
28.Younis N, Williams S, Ammori S, Soran H. Role of Aspirin in the Primary Prevention of Cardiovascular Disease in Diabetes Mellitus: A Meta-analysis. 2010; 11: 1459-66.
29.Moulinath Banerjee, Naveed Younis, Handrean Soran. Vildagliptin in clinical practice: a review of literature. Expert Opin Pharmacother 2009;10(16):2745-57.
30.Yared Dneguss, Naveed Younis, Handrean Soran. The role of insulin detemir in the management of type 2 diabetes. Journal of Vascular Health and Risk Management 2009; 5: 553-60.
31.Handrean Soran, Valentine Charlton-Menys, Nahla Younis, Paul N Durrington. Variation in Paraoxonase-1 and atherosclerosis Current Opinion in Lipidology 2009; 20: 265-74.
32.Naveed Younis, Steve Williams, Handrean Soran. Aspirin Therapy and Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. Diabetes, Obesity and Metabolism 2009 Jun 16. [Epub ahead of print].
33.Cardiovascular disease and intensive glucose lowering in Type 2 Diabetes. Naveed younis, Handrean Soran, Mohammed Hassanein. QMJ 2009; 102: 293-6..
34.Yared Demssie, Handrean Soran, Naveed younis. Tight glycaemic control and cardiovascular disease in Type 2 diabetes. BJHM 2009; 71: 31-34.
35.The role of Renin Angiotensin system blocking in Atrial Fibrillation. H Soran, H Ziglam, M Al-Nagaar, N Younis. Accepted for publication in Acta Cardiologica 2008; 63: 457-465.
36.Hypercholesterolaemia and its management. Deepak Bhatnagar, Handrean Soran and Paul N Durrington. BMJ 2008; 337: a993. doi: 10.1136/bmj.a993.
37.Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Nahla Younis, Valentine Charlton-Menys, Reena Sharma, Handrean Soran, Paul N Durrington. Atherosclerosis. Published on line.
38.Rosuvastatine: efficacy, safety and clinical effectiveness. Handrean Soran, Paul Durrington. Expert Opinion Pharmacotherapy 2008; 9: 2145-60.
39.Lipoproteins glycation and vascular damage. Nahla Younis, Valentine Charlton-Menys, Reena Sharma, Handrean Soran, Paul N Durrington. Current Opinion in Lipidology 2008; 19: 378-84.
40.Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. Muhammad N Choudhry, Handrean Soran, Hisham Ziglam. QJM. 2008; 101: 445-8.
41.Type 2 diabetes is an independent risk factor for recurrence of atrial fibrillation after a successful DC cardioversion. H Soran, N Younis, J Silas P, Currie, IR Jones, G Gill. QJM 2008; 101: 181-7.
42.Atkins diet and it is role in managing type 2 diabetes. J Worth & H Soran. QJM 2007; 100: 659-663.
43.H Soran, B Barzangy, N Younis. Benefits of insulin therapy following an acute myocardial infarction revisited. QJM 2006; 60: 1319-1322.
44.H Soran, N Younis, F Joseph, A Scott. Haemangiopericytoma Induced Hypoglycaemia Treated Successfully with radiotherapy. International Journal of Clinical Practice 2006; 99: 635-637.
45.H Soran, N Younis. Insulin detemir: a new basal Insulin. Diabetes, Obesity and Metabolism 2006; 8: 26-30.
46.H Soran, FC Wu. Endocrine aetiology of erectile dysfunction. International Journal of Andrology 2005; 28: 28-34.
47.H Soran, Z Alio, T Pattison, G Burrows, G Cook, N Kong. Management of hyponatraemia; are we doing enough? QJM 2005; 98: 620-621.
48.H Soran, SPY Wong, JL Lloyd. Left ventricular hypertrophy could be the only presenting feature of phaeochromocytoma. The Endocrinologist 2005; 15: 279-280.
49.N Younis & H Soran. Prevention of type 2 diabetes: recent advances. QJM 2004: 97: 451-455.
50.H Soran, J Wilding, I MacFarlane. Body weight and prolactinoma: A retrospective study. International Journal of Obesity 2004; 28: 183.
51.H Soran, JP Vora, N Younis, F Joseph, P English, JP Neoptolemus, F Campbell, IR Jones. Multiple endocrine neoplasia caused by a new novel mutation. The Endocrinologist 2004; 14: 129-130.
52.F Joseph, N Younis, H Soran, S Stanaway, DB Jones. Blood pressure targets in a hospital diabetes population. Practical Diabetes International 2003; 20: 276-282.
53.N Younis and H Soran. Relapsing polychondritis in the NORD Guide to Rare Disorders. Lippincott, Williams & Wilkins. Philadelphia, PA; 2003: 29-31.
54.H Soran, L Murray, SPY Wong, P Currie, IR Jones. Digoxin toxicity: an unusual presentation of infective endocarditis. British Journal of Cardiology 2003; 10: 308-09.
55.H Soran, R Salim, DW Galvani. Recurrent Clostridium difficle infection in a patient with multiple myloma: should we look for a second pathology? The CME Journal of Gastroenterology, Hepatology and Nutrition 2003; 5: 49-50.
56.H Soran, N Younis, G Gill. Type 1 diabetes and coeliac disease: a review article. J R Coll Physicians Edinb 2002; 32: 178-188.
57.N Younis, H Soran, DB Jones. Insulin glargine: a new long-acting Insulin.. QJM 2002; 95: 757-761.
58.N Younis, H Soran, A El-Houni, IR Jones. Management of amiodarone induced thyrotoxicosis. Hospital Medicine 2002; 63: 546-549.
59.A El-Houni, N Younis, H Soran, Bowen-Jones D. Diarrhoea soon after levothyroxine replacement therapy. QJM 2002; 95: 125-126.
60.H Soran, M Lewis, PJ Whorwell. Angiodysplasia: Should we concentrate on aortic valve rather than colon? International Journal of Clinical Practice 2001; 56: 155-156.
61.H Soran, PW Bishop, F Knox, PJ Whorwell. An unusual presentation of ulcerative colitis. CME Journal Gastroenterology, Hepatology and Nutrition 2001; 4: 74-76.
62.N Younis, AA Khaleeli, H Soran, PG Monteith. Inflammatory pseudotumour of the liver associated with diabetes mellitus. International Journal of Clinical Practice 2001; 55: 717-719.
63.H Soran, H Osman, N Younis, SA Sukumar, DA Taberner. Could factor five Leiden disease cause bilateral adrenal haemorrhage? QJM 2001; 94: 721-722.
64.H Soran. Malaria may present with itchy urticaroid rash and fever. Middle-East Journal of Emergency Medicine 2001; 1: 35-36.
65.H Soran. Oral hypoglycaemic agents: past, present and future. Diabetes International 2000; 10: 77- 80.
Committee memberships:
• Simon Broome Scientific Committee, HEART UK.
• New Medicine sub-group, Greater Manchester Medicine Management Committee.
• Heart UK’s national apheresis Committee.
• Member of Lipid, metabolic and vascular section council, Royal Society of Medicine.
• Heart UK Familial Hypercholesterolaemia NICE guideline implementation group.
Post graduate students:
Previous students:
Dr Rahul Yadav, MD student- awarded.
Dr Salam Hama, PhD student-awarded.
Current students:
Dr Jonathan Schofield, second year MD student
Mrs Tarza Siamansoor, second year PhD student
Mrs Suha Saeed, second year PhD student.
Mrs Yifen Liu, PhD student.
Laboratory techniques available in our laboratory:
There is a Comprehensive range of laboratory techniques available including:
1. Various lipoprotein separation techniques including ultracentrifugation and precipitation. Routine isolation of different density lipoproteins, including chylomicrons, very low density lipoprotein (VLDL, density 1.006 g/ml), intermediate density LDL (IDL, density 1.006-1.019 g/ml)), total low density LDL (density 1.019-1.063 g/ml), small-dense LDL (density 1.044-1.063 g/ml), total high-density lipoprotein (HDL, density 1.063-1.21 g/ml)) and HDL2 (density 1.063-1.125 g/ml) and HDL3 (density 1.125-1.21 g/ml). We also can measure apolipoproteins (apoB, apoA-I, apoA-II, apoE and lipoprotein(a)) in various lipoprotein subfractions.
2. Separate glycated from non-glycated lipoproteins by m-aminophenylboronate affinity column chromatography (Gambino, Uberti et al. 2004).
3. Measure total apoB by the in-house developed ELISA method together with the glycated chromatography elutes.
4. Measure the overall change in the negative charge caused by glycation by measuring the relative electrophoretic mobility (REM), using agarose gel electrophoresis modified method of (Noble 1968).
5. Measure the degree of lipoprotein modification by trinitrobenzenesulfonic acid (TNBS) assay (Habeeb 1966).
6. Measure the amount of lipid peroxides formed during in vitro glycation (el-Saadani, Esterbauer et al. 1989).
7. A validated in house developed method to measure glycated apoB.
8. An in house developed method to measure MPO.
9. A validated paraoxonase activity measurement.
10.In vitro and in vivo lipoprotein glycation (apoAI, apoB, apoE).
11.In vitro and in vivo LDL oxidation.
12.In vitro cell culture studies.
13.Different Immunoassay techniques including hormones, cardiovascular biomarkers and apolipoproteins.
14.Determination of cholesteryl ester transfer activity and lecithin cholesterol acyl transferase activity using radiolabelled cholesterol.
15.In addition, many haematological inflammatory markers, and adipokines relevant to atherosclerosis and diabetes are available.
16.Macrophage cholesterol efflux in vitro studies.
17.We have access to the Central Manchester University Hospitals laboratory facilities.
Clinical population:
Our tertiary centre lipid clinics (4 clinics per week: 2 clinics per week at Manchester Royal Infirmary, 1 weekly clinic at Trafford General Hospital and 1 weekly clinic at Altrincham General Hospital) attract a large number of referrals from primary as well as secondary care. We currently receive more than 8 new referrals each week and the number continued to increase gradually over the last 12 months. We have more than 3500 patients in our lipid clinics, in a recent audit we found that 25% of our patients are Famililial Hypercholesterolaemia cases (we have 9 homozygous cases), 24% are known to have type 2 diabetes, 4% are patients with severe hypertriglyceridaemia syndromes and 30% are patients with mixed dyslipidaemia and familial combined hyperlipidaemia. We also manage a number of rare insulin resistance syndromes, lipodystrophy cases, very rare lipoprotein metabolism abnormality syndromes, obesity and patients who undergone bariatric surgery. We also collaborate and established a common database with 3 other lipid clinics in Greater Manchester, all 3 together they have similar number of patients. Our centre provides LDL apheresis for patients with Homozygous Familial Hypercholesterolaemia and other severe hyperlipidaemias.
We also have access to recruit patients from Hypertension, cardiology clinics, coronary care unit, cardiac rehabilitation unit, stroke clinics, stroke unit and Diabetes Clinics at our hospital. We also have access and collaboration with University Hospital South Manchester and Trafford General Hospital diabetes centres and Stockport Lipid clinic, we could use these clinics as PIC sites. We also have access to recruit patients from Primary Care, Local General Practitioner Surgeries. All our research Nurses have research passport.
We have access to admit patients to programmed investigation unit and Manchester Wellcome Trust Clinical Research Facility for further investigations and for studies require 24 hour stay. We also have access to patients who are undergoing glucose tolerance test.
Through our collaborations we have access to recruit large numbers of morbidly obese patients, patients with hypertension, hyperlipidaemia and diabetes. We also do collaborate and have a system in place to recruit patients from other lipid and diabetes clinics in North West including University Hospital South Manchester, Stockport, Salford and Tameside Hospitals.
We also have established data base that includes all our ~3000 lipid clinics patients (22% are also diabetics). This data base is systematic and could be used for audit and research projects. We have access to recruit patients from general medical clinics, diabetes clinics, in patients in Manchester Royal Infirmary and also collaborating with other colleagues in other trusts to increase patient recruitment.
Academic research programs:
1. Atherogenicity of glycated LDL in vivo and in vitro.
2. Effect of HDL, PON1 on in vitro glycation of LDL and foam cell formation
3. Distribution of apoE across different lipoproteins and the influence of apoE genotype.
4. Effect of high versus low dose atorvastatin on lipoproteins, glycated LDL, ApoE distribution and cardiovascular risk factors.
5. Effect of Tredaptive on serum lipoproteins, lipoprotein metabolism, Glycation of apolipoprotein B, oxidative stress, aopolipoprotein B distribution across lipoprotein particles and HDL anti-inflammatory index.
6. Factors affecting paraoxonase-1 activity and effect of weight loss after bariatric surgery on paraoxonase-1 activity, lipoprotein metabolism, cardiovascular risk factors, fat inflammation, vascular and endothelial function.
7. Obstructive sleep apnoea and its influence on developing different cardiovascular disease, diabetes, dyslipidaemia, Paraoxnonse-1 activity, oxidative stress, peripheral inflammation and different cardiovascular risk factors/markers, and adipose tissue inflammation in super-obese patients undergoing bariatric surgery.
8. Atherogenicity in type 1 and type 2 diabetes
9. Apolipoprotein B100 provides a more consistent goal of statin treatmenyt than LDL-C and non-HDL-C particularly in patients with hypertriglyceridaemia.
10.Genetic and acquired factors contributing to obesity and cardiovascular risk in women (prospective study of 20 000 UK women).
11.Identifying mutations causing Sever Hypertriglyceridaemia and genotype-phenotype relationship.
12.The role of microRNAs in atherosclerosis.

Commenti chiusi